INFINITY: neoadjuvant or definitive tremelimumab with durvalumab in MSI GAC/GEJAC

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, explores the Phase II INFINITY trial (NCT04817826) of tremelimumab plus durvalumab as neoadjuvant or definitive treatment in MSI high, resectable gastric and gastroesophageal junction adenocarcinoma (GAC/GEJAC). Non-operative management was found to be feasible in this cohort of patients and the treatment additionally demonstrated safety with manageable adverse events and maintained quality of life. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.